Morehouse Total Cancer Care Protocol is a study to help improve cancer care by discovering new ways to treat and understand cancer. The study collects biomarkers (special substances in the body that can indicate disease) and finds new drug targets. It involves gathering blood, tissue, and other samples from African American cancer patients or those at risk. This is not a treatment study; instead, it's a longitudinal study, which means it follows patients over a long time to create a central collection of cancer-related data. The aim is to use this data for personalized medicine, which means tailoring healthcare to individual patients. Participants must be 18 or older and either have cancer or be at risk. They need to give informed consent, meaning they agree to share their medical records, survey answers, and extra tissues from planned surgeries. The study continues for as long as the participant is alive.

• The study is not a treatment trial; it focuses on data collection.
• Participants need to give consent for their medical information and samples to be used.
• There are no risks mentioned, but participants are followed for life for data collection.